Extension Study of MT-1303

NCT01890655 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

367

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing-remitting Multiple Sclerosis

Interventions

DRUG: MT-1303-Low
DRUG: MT-1303-Middle
DRUG: MT-1303-High

Sponsor

Tanabe Pharma Corporation